Pharmacokinetics/Pharmacodynamics
Learning Objectives
Describe the changes in critically ill patients that
alter drug absorption.
Depict the effects of changing hepatic blood flow,
intrinsic activity, and protein binding on drug
metabolism.
Differentiate between different critically ill patient
populations and the expected pharmacokinetic (PK)
changes.
Identify the desired pharmacodynamic variables
associated with efficacy in select drugs.
α1-Acid glycoprotein
AKI
Acute kidney injury
ARC
Augmented renal clearance
AUC
Area under the curve
AUC/MIC
Ratio of area under the curve to the
minimum inhibitory concentration for
the bacterial pathogen
| AUC0-24/MIC | Ratio of area under the curve for 24 |
|---|
hours to the minimum inhibitory
concentration for the bacterial pathogen
CKD
Chronic kidney disease
Cmax/MIC
Ratio between the maximum drug
concentration and the minimum
inhibitory concentration for the bacterial
pathogen
fT>MIC
Free drug concentration time above the
minimum inhibitory concentration for
the bacterial pathogen
ECMO
Extracorporeal membrane oxygenation
GFR
Glomerular filtration rate
ICU
Intensive care unit
MIC
Minimum inhibitory concentration
PD
Pharmacodynamic(s)
PK
Pharmacokinetic(s)
TBI
Traumatic brain injury
TDM
Therapeutic drug monitoring
Vd
Volume of distribution
Self-Assessment Questions
Answers and explanations to these questions can be
found at the end of this chapter.
J.H. is a 30-year-old man admitted to the inten-
sive care unit (ICU) for septic shock. He initially
received 30 mL/kg of normal saline for intravenous
fluid resuscitation. He required further fluid admin-
istration to improve his pulse pressure variation.
Despite prophylaxis with enoxaparin 30 mg subcu-
taneously every 12 hours, J.H. has a proximal deep
venous thrombosis. Which pharmacokinetic (PK)
alteration most likely contributed to this therapeutic
failure?
secondary to decreased volume of distribution
(Vd).
decreased absorption.
anti-Xa
activity
secondary
to
decreased hepatic metabolism.
anti-Xa
activity
secondary
to
decreased renal elimination.
Questions 2–4 pertain to the following case.
E.W. is a 48-year-old man (height 70 inches, weight 85
kg) admitted to the trauma ICU after a motorcycle col-
lision. E.W. presents with a traumatic brain injury (TBI;
head computed tomography [CT] reveals a depressed
skull fracture, frontal subarachnoid hemorrhage, and
right intraparenchymal hemorrhage), right acetabulum
fracture, bilateral rib fractures, and abdominal trauma.
According to his abdominal CT, E.W. must go to the
operating room for an exploratory laparotomy for repair
of several serosal tears. After surgery, E.W. requires sig-
nificant resuscitation in his first 24 hours of admission
(5 L of normal saline). He is made NPO to allow bowel
rest.
E.W.’s laboratory values are as follows: serum cre-
atinine (SCr) 1.1 mg/dL, blood urea nitrogen (BUN) 17
mg/dL, and white blood cell count (WBC) 19 × 103 cells/
mm3. The patient’s pulmonary artery catheterization val-
ues are cardiac index 4.2 L/minute/m2 (normal 2.8–3.6
L/minute/m2) and pulmonary artery wedge pressure
16 mm Hg. His medication therapy includes a fentanyl
continuous infusion of 75 mcg/hour, a propofol con-
tinuous infusion of 15 mcg/kg/minute, pantoprazole 40
mg intravenously every 24 hours, enoxaparin 30 mg